Angelica C. Kottkamp

Infectious Disease

462 1st Ave
New York, NY 10016

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost.

The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost.

Journal: Science translational medicine

Published: February 25, 2026

Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study.

Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study.

Journal: The Lancet. Infectious diseases

Published: December 23, 2025

A comparison of two- and three-dose MVA-BN mpox vaccination series on anti-monkeypox virus immunity.

A comparison of two- and three-dose MVA-BN mpox vaccination series on anti-monkeypox virus immunity.

Journal: NPJ vaccines

Published: November 10, 2025

The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

Journal: Vaccine

Published: October 31, 2025

Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.

Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 10, 2025

Correction for Oom et al., "The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response".

Correction for Oom et al., "The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response".

Journal: Journal of virology

Published: September 04, 2025

The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.

The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.

Journal: Journal of virology

Published: March 31, 2025

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.

Journal: The Journal of infectious diseases

Published: December 31, 2024

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

Journal: Nature communications

Published: July 19, 2024

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 06, 2024

Antibody Titers against Mpox Virus after Vaccination.

Antibody Titers against Mpox Virus after Vaccination.

Journal: The New England journal of medicine

Published: December 13, 2023

Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City.

Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City.

Journal: Journal of telemedicine and telecare

Published: August 26, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026